NASDAQ$ACAD
ACADIA Pharmaceuticals Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Acadia Pharmaceuticals reported an 8% increase in NUPLAZID net sales and reiterated its full-year net sales guidance.
Acadia Pharmaceuticals reported first quarter 2022 financial results, with NUPLAZID net sales increasing by 8% compared to the first quarter of 2021. The company is focused on preparing for the upcoming Advisory Committee meeting for pimavanserin in Alzheimer's disease psychosis and the NDA submission for trofinetide in Rett syndrome.
- NUPLAZID net sales increased by 8% compared to Q1 2021.
- FDA Advisory Committee meeting scheduled for June 17, 2022, to review sNDA for pimavanserin in Alzheimer’s disease psychosis (ADP).
- FDA is targeting an August 4, 2022, action date for the resubmitted sNDA for pimavanserin for the treatment of ADP.
- Trofinetide for the treatment of Rett syndrome remains on track for an NDA submission around mid-year 2022.
Headline financials
Revenue & EPS history
ACADIA · Revenue · Quarterly
$115M
Revenue by segment
ACADIA · $115M total across 1 segment · Q1 2022
- NUPLAZID$115M+8.4%100.0%
Forward guidance
Acadia is reiterating its previously provided guidance ranges
Tailwinds
- NUPLAZID net sales guidance of $510 to $560 million.
- GAAP R&D guidance of $355 to $375 million, which includes approximately $25 million of stock-based compensation expense.
- GAAP SG&A guidance of $360 to $380 million, which includes approximately $45 million of stock-based compensation expense.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.9%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.6%
Avg return
30 days after
42%
27 / 65 earnings
Positive
+23.7%
Q3 2016
Best reaction
-22.9%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.9% | -2.5% | -3.6% | |
| Q4 2025 | -1.4% | -9.9% | -16.9% | |
| Q3 2025 | -2.9% | +6.2% | +22.9% | |
| Q1 2025 | +14.4% | +16.1% | +48.4% | |
| Q4 2024 | +1.8% | -3.9% | -10.2% | |
| Q3 2024 | +14.7% | +21.8% | +15.2% | |
| Q2 2024 | -17.6% | -15.1% | -11.9% | |
| Q1 2024 | -11.8% | -12.0% | -13.7% | |
| Q4 2023 | -8.3% | -7.3% | -28.6% | |
| Q3 2023 | +5.0% | +2.5% | -1.4% | |
| Q2 2023 | -6.0% | -7.4% | -4.0% | |
| Q1 2023 | -2.3% | -2.1% | +12.3% | |
| Q4 2022 | +9.4% | +7.5% | +0.3% | |
| Q3 2022 | -6.6% | -8.6% | -0.6% | |
| Q2 2022 | -1.3% | -0.2% | +2.5% | |
| Q1 2022 | -4.9% | -17.3% | -9.6% | |
| Q4 2021 | -2.2% | -6.2% | -4.8% | |
| Q3 2021 | +7.7% | +3.1% | +8.8% | |
| Q2 2021 | -11.0% | -11.4% | -22.4% | |
| Q1 2021 | +7.3% | +7.7% | +21.4% | |
| Q4 2020 | -4.9% | -0.4% | -48.0% | |
| Q3 2020 | +4.2% | +7.4% | +16.4% | |
| Q2 2020 | +0.3% | -5.1% | -12.1% | |
| Q1 2020 | +5.3% | +2.5% | -5.3% | |
| Q4 2019 | -3.9% | +7.6% | -4.5% | |
| Q3 2019 | +0.4% | +0.4% | +7.2% | |
| Q2 2019 | +14.7% | +14.4% | +10.6% | |
| Q1 2019 | +6.0% | +11.4% | -0.2% | |
| Q4 2018 | +7.5% | +12.0% | +12.2% | |
| Q3 2018 | -7.7% | -12.9% | -12.7% | |
| Q2 2018 | -2.0% | +0.7% | -1.1% | |
| Q1 2018 | +15.6% | +15.8% | +14.3% | |
| Q4 2017 | -22.9% | -26.8% | -30.5% | |
| Q3 2017 | -9.6% | -12.1% | -7.6% | |
| Q2 2017 | +8.6% | +2.1% | +17.1% | |
| Q1 2017 | -8.6% | -8.7% | -17.8% | |
| Q4 2016 | -8.1% | -7.4% | -14.4% | |
| Q3 2016 | +23.7% | +32.8% | +24.9% | |
| Q2 2016 | -1.8% | -10.3% | -15.0% | |
| Q1 2016 | +0.4% | — | — | |
| Q4 2015 | +2.2% | — | — | |
| Q3 2015 | -13.1% | — | — | |
| Q2 2015 | -17.8% | — | — | |
| Q1 2015 | +3.2% | — | — | |
| Q4 2014 | +1.5% | — | — | |
| Q3 2014 | -0.7% | — | — | |
| Q2 2014 | +3.1% | — | — | |
| Q1 2014 | -8.4% | — | — | |
| Q4 2013 | -4.8% | — | — | |
| Q3 2013 | -7.8% | — | — | |
| Q2 2013 | -5.6% | — | — | |
| Q1 2013 | -4.4% | — | — | |
| Q4 2012 | -6.0% | — | — | |
| Q3 2012 | +11.0% | — | — | |
| Q2 2012 | -0.7% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.6% | — | — | |
| Q4 2009 | +0.6% | — | — | |
| Q3 2011 | -5.0% | — | — | |
| Q4 2010 | -2.9% | — | — | |
| Q2 2011 | -2.9% | — | — | |
| Q1 2011 | -4.1% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q2 2010 | -7.5% | — | — | |
| Q1 2010 | +11.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro